Bone Biologics Corp Stock Performance
| BBLG Stock | USD 1.04 0.01 0.97% |
The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bone Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bone Biologics is expected to be smaller as well. At this point, Bone Biologics Corp has a negative expected return of -0.28%. Please make sure to confirm Bone Biologics' maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Bone Biologics Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Bone Biologics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Last Split Factor 1:8 | Dividend Date 2018-07-24 | Last Split Date 2023-12-20 |
1 | Disposition of 5274 shares by Soo B Chia of Bone Biologics at 1.58 subject to Rule 16b-3 | 12/13/2024 |
2 | Acquisition by Frelick Jeff of 54110 shares of Bone Biologics at 0.9678 subject to Rule 16b-3 | 01/15/2025 |
3 | Discretionary transaction by Hankey Don of 7860760 shares of Bone Biologics at 1.0 subject to Rule 16b-3 | 02/11/2025 |
| Begin Period Cash Flow | 7.5 M |
Bone |
Bone Biologics Relative Risk vs. Return Landscape
If you would invest 132.00 in Bone Biologics Corp on November 19, 2024 and sell it today you would lose (28.00) from holding Bone Biologics Corp or give up 21.21% of portfolio value over 90 days. Bone Biologics Corp is currently does not generate positive expected returns and assumes 4.7761% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Bone, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bone Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bone Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bone Biologics Corp, and traders can use it to determine the average amount a Bone Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0586
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BBLG |
Estimated Market Risk
| 4.78 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.28 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bone Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bone Biologics by adding Bone Biologics to a well-diversified portfolio.
Bone Biologics Fundamentals Growth
Bone Stock prices reflect investors' perceptions of the future prospects and financial health of Bone Biologics, and Bone Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bone Stock performance.
| Return On Equity | -1.09 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | (1 M) | ||||
| Shares Outstanding | 2.46 M | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.68 X | ||||
| EBITDA | 479.57 K | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 831.4 K | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 1.81 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Earnings Per Share | (1.46) X | ||||
| Market Capitalization | 2.56 M | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
About Bone Biologics Performance
By analyzing Bone Biologics' fundamental ratios, stakeholders can gain valuable insights into Bone Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bone Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bone Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 368.20 | 327.29 | |
| Return On Tangible Assets | (2.15) | (2.26) | |
| Return On Capital Employed | (3.73) | (3.54) | |
| Return On Assets | (2.15) | (2.26) | |
| Return On Equity | (3.54) | (3.36) |
Things to note about Bone Biologics Corp performance evaluation
Checking the ongoing alerts about Bone Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bone Biologics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bone Biologics Corp generated a negative expected return over the last 90 days | |
| Bone Biologics Corp has some characteristics of a very speculative penny stock | |
| Bone Biologics Corp has high historical volatility and very poor performance | |
| Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Bone Biologics Corp has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Discretionary transaction by Hankey Don of 7860760 shares of Bone Biologics at 1.0 subject to Rule 16b-3 |
- Analyzing Bone Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bone Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Bone Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bone Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bone Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bone Biologics' stock. These opinions can provide insight into Bone Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bone Stock analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |